Table 1

Clinical, surgical, and pathological characteristics of endometrial cancer patients who underwent bilateral sentinel lymph node mapping with or without lymphadenectomy at the participating centers during the study period

CharacteristicTotal
(n=1570)
SLN removal only
(n=1416)
SLN removal and LND
(n=154)
Age at surgery (years), mean (SD)63.3 (10.4)63.5 (10.6)62.2 (8.9)
BMI (kg/m2)
 N15241372152
 Mean (SD)32.4 (8.6)32.4 (8.5)32.8 (9.0)
Surgical approach
 Laparotomy45 (2.9)31 (2.2)14 (9.1)
 Vaginal50 (3.2)44 (3.1)6 (3.9)
 Robotic1411 (89.9)1280 (90.4)131 (85.1)
 Laparoscopy64 (4.1)61 (4.3)3 (1.9)
Histology
 Endometrioid1335 (85.0)1214 (85.7)121 (78.6)
 Serous117 (7.5)98 (6.9)19 (12.3)
 Clear cell32 (2.0)26 (1.8)6 (3.9)
 Undifferentiated6 (0.4)6 (0.4)0
 Carcinosarcoma24 (1.5)22 (1.6)2 (1.3)
 Mixed45 (2.9)39 (2.8)6 (3.9)
 Other11 (0.7)11 (0.8)0
Histology
 Non-endometrioid211 (13.4)180 (12.7)31 (20.1)
 Endometrioid*1359 (86.6)1236 (87.3)123 (79.9)
FIGO 2009 stage
 IA1143 (72.8)1066 (75.3)77 (50.0)
 IB200 (12.7)174 (12.3)26 (16.9)
 II49 (3.1)41 (2.9)8 (5.2)
 IIIA/B54 (3.4)47 (3.3)7 (4.5)
 IIIC1100 (6.4)76 (5.4)24 (15.6)
 IIIC212 (0.8)4 (0.3)8 (5.2)
 IV12 (0.8)8 (0.6)4 (2.6)
FIGO grade
 1776 (49.4)737 (52.0)39 (25.3)
 2430 (27.4)378 (26.7)52 (33.8)
 3364 (23.2)301 (21.3)63 (40.9)
Myometrial invasion
 None366 (23.3)348 (24.6)18 (11.7)
 <50%877 (55.9)799 (56.4)78 (50.6)
 ≥50%327 (20.8)269 (19.0)58 (37.7)
LVSI
 Absent1308 (83.3)1203 (85.0)105 (68.2)
 Present256 (16.3)209 (14.8)47 (30.5)
 Unknown6 (0.4)4 (0.3)2 (1.3)
Pelvic lymph nodes
 Negative1383 (88.1)1268 (89.5)115 (74.7)
 ITC75 (4.8)66 (4.7)9 (5.8)
 Micrometastases53 (3.4)42 (3.0)11 (7.1)
 Macrometastases59 (3.8)40 (2.8)19 (12.3)
Tumor size (mm)
 N14061260146
 Mean (SD)37.1 (21.5)36.1 (20.9)46.0 (24.4)
Tumor diameter
 ≤2 cm284 (18.1)269 (19.0)15 (9.7)
 >2 cm1122 (71.5)991 (70.0)131 (85.1)
 Unknown164 (10.4)156 (11.0)8 (5.2)
Number of lymph nodes removed†, median (IQR)
 SLN3 (2, 4)3 (2, 4)3 (2, 4)
 Pelvic LND12 (4, 21)12 (4, 21)
 Para-aortic LND7 (3, 15)4 (2, 7)10 (5, 16)
 Total (SLN and pelvic LND)3 (2, 5)3 (2, 4)15 (9, 24)
 Total (SLN, pelvic LND, and para-aortic LND)3 (2, 5)3 (2, 4)17 (9, 28)
  • Variables are reported for the entire population and stratified by type of lymph node evaluation.

  • Results presented are number (N) and percentage (%) unless otherwise specified.

  • *Includes 24 mixed or other histotypes that were reclassified as endometrioid after review of the electronic medical record (22 sentinel lymph node (SLN) removal only, 2 SLN removal and lymphadenectomy).

  • †Among those with listed lymph node assessment.

  • BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; IQR, interquartile range; ITC, isolated tumor cells; LAVH, laparoscopic assisted-vaginal hysterectomy; LND, lymphadenectomy; LVSI, lymphovascular space invasion; SD, standard deviation; SLN, sentinel lymph node.